Bruno Calabretta

US Patent:

54279160, Jun 27, 1995

Filed:

Aug 10, 1994

Appl. No.:

8/288151

Inventors:

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Assignee:

Temple University of the Commonwealth System of Higher Education - Philadelphia PA

International Classification:

C12Q 168
C07H 2102
A61K 4300
A61K 4900

US Classification:

435 6

Abstract:

The effectiveness of selected antineoplastic agents may be determined in individual patients by comparing the level of expression of one or more selected growth-regulated genes in neoplastic cells taken from the patient before and shortly after the initiation of therapy. A decrement in expression is prognostic of eventual remission, while a lack of decrement indicates that remission is unlikely. The test may also be accomplished by comparing the level of expression of growth-regulated genes in neoplastic cells in culture before and after incubation of the cells with the selected antineoplastic agents.

US Patent:

59898496, Nov 23, 1999

Filed:

Jun 5, 1995

Appl. No.:

8/461286

Inventors:

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Assignee:

Temple University of the Commonwealth System of Higher Education - Philadephia PA

International Classification:

C12Q 102
C12Q 168
C12N 500
A61K 4800

US Classification:

435 29

Abstract:

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-kit gene. These "antisense" oligonucleotides are hybridizable to the c-kit mRNA transcript. Such oligonucleotides are useful in selectively inhibiting proliferation of erythroid cells, particularly in disorders characterized by an elevated hematocrit due to over-production of erythrocytes. The antisense oligomers also have activity agent hematologic neoplastic cells and are therefore suitable as bone marrow purging agents.

US Patent:

57340390, Mar 31, 1998

Filed:

Sep 15, 1994

Appl. No.:

8/306691

Inventors:

Bruno Calabretta - Philadelphia PA
Tomasz Skorski - Philadelphia PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

C07H 2104

US Classification:

536 245

Abstract:

Therapeutic combinations of two or more antisense oligonucleotides are provided. At least one first antisense oligonucleotide specific for a cytoplasmic oncogene or proto-oncogene and at least one second antisense oligonucleotide specific for a nuclear oncogene or proto-oncogene are combined for treatment of a neoplastic disease. The first antisense oligonucleotide may be specific for, e. g. , a ras or raf gene, or an oncogene which codes for a protein tyrosine kinase. The nuclear gene-targeting antisense oligonucleotide preferably may be specific for a nuclear oncogene or proto-oncogene which encodes a transcriptional factor. The combined oligonucleotides have enhanced activity against neoplastic disease.

US Patent:

50988905, Mar 24, 1992

Filed:

Oct 27, 1989

Appl. No.:

7/427659

Inventors:

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Assignee:

Temple University-of the Commonwealth System of Higher Education - Philadelphia PA

International Classification:

A61K 3170
C07H 2100

US Classification:

514 44

Abstract:

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents.

US Patent:

56522223, Jul 29, 1997

Filed:

Nov 15, 1993

Appl. No.:

8/152621

Inventors:

Bruno Calabretta - Philadelphia PA
Alan M. Gewirtz - Philadelphia PA

Assignee:

Temple University-of The Commonwealth System of Higher Education - Philadelphia PA

International Classification:

A61K 4800
C07H 2104
C12N 1500
C12N 500

US Classification:

514 44

Abstract:

Leukemias characterized by the presence of the Philadelphia chromosome and the expression of the hybrid bcr-abl gene are treated with antisense oligonucleotides complementary to a target sequence of the bcr-abl mRNA transcript including the breakpoint junction. Individual chronic myelogoneous leukemia patients or Philadelphia chromosome-positive acute lymphocytic leukemia patients are treated by first sequencing the individual's bcr-abl breakpoint junction, and then administering antisense oligonucleotides complementary thereto. The oligonucleotides are designed to hybridize specifically to the bcr-abl breakpoint junction without substantial cross hybridization to untranslocated c-abl sequences. Treatment may comprise in vivo administration of antisense oligonucleotides, or ex vivo treatment such as bone marrow purging.

US Patent:

58177833, Oct 6, 1998

Filed:

Jun 20, 1996

Appl. No.:

8/667023

Inventors:

Bruno Calabretta - Philadelphia PA
Donatella Venturelli - Philadelphia PA
Robert V. Martinez - Philadelphia PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

C07H 2104

US Classification:

536 231

Abstract:

DR-nm23 protein is disclosed. A nucleotide sequence encoding the same and fragments thereof, recombinant expression vectors that comprise the nucleotide sequence, host cell comprising the recombinant expression vectors and methods of making DR-nm23 protein are disclosed. Oligonucleotide molecules comprising a nucleotide sequence complementary to a portion of the nucleotide sequence that encodes DR-nm23 and methods of using the same to inhibit DR-nm23 expression are disclosed. Isolated antibodies that bind to an epitope on DR-nm23 are disclosed. Methods of tracking the progress on chronic myelogenous leukemia and methods of detecting the onset of blast crisis phase in an individual with chronic myelogenous leukemia are disclosed.

US Patent:

53626311, Nov 8, 1994

Filed:

Jul 29, 1993

Appl. No.:

8/099868

Inventors:

Bruno Calabretta - Philadelphia PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

C12N 522
C12N 1519

US Classification:

435 695

Abstract:

A c-myb transfected cell line capable of producing a selected growth factor is provided. In a preferred embodiment, human glioblastoma cells are co-transfected with a first plasmid containing human c-myb DNA and second plasmid containing the gene encoding hygromycin resistance. Methods of producing selected growth factors employing cell line are also provided.

US Patent:

20220362254, Nov 17, 2022

Filed:

Aug 21, 2020

Appl. No.:

17/636997

Inventors:

- Philadelphia PA, US
Bruno Calabretta - Philadelphia PA, US
Svetlana Petruk - Voorhees NJ, US
Patrizia Porazzi - Philadelphia PA, US
David Deming - Philadelphia PA, US

International Classification:

A61K 31/5377
A61K 31/573
A61K 31/42
A61K 31/519
A61P 35/02

Abstract:

The present invention relates to methods and compositions for the treatment of cancer in a subject in need thereof by treatments that reprogram the cancer cells.